Investor Relations Investor Relations Latest News May 13, 2022 InMed Pharmaceuticals Reports Third Quarter Fiscal 2022 Financial Results and Provides Business Update May 05, 2022 InMed to Supply Rare Cannabinoids to Radicle Science’s “Radicle Energy Study” to Assess the Health Effects of THCV Apr 28, 2022 InMed Expands Patent Portfolio with Novel Cannabinoid Analogs and Advances Collaboration Agreement with Leading Cannabinoid Research Expert Apr 21, 2022 InMed Commercializes Cannabidivarin (CBDV), Expanding its Rare Cannabinoid Portfolio for the Health and Wellness Sector btn News See All News Latest Presentation Corporate Presentation - April 2022 Corporate Presentation - April 2022 8 MB More Presentations Latest Events May 23 - May 26, 2022 H.C. Wainwright Global Investment Conference May 11, 2022 Canaccord Genuity’s 6th Annual Global Cannabis Conference April 20 - April 21, 2022 Benzinga Spring 2022 Cannabis Capital Conference btn Events See All Events Videos More Videos btn Stock See All Stock Analyst Coverage Scott R. Henry CFA ROTH Capital Partners shenry@roth.com +1 (406) 425-0563 Ken Mestemacher Edison Research Group kmestemacher@edisongroup.com +1 (646) 653-7027 Raghuram Selvaraju H.C. Wainwright rselvaraju@hcwco.com +1 (212) 916-3966 Latest Financial Reports Show all Q3 2022 Quarterly Press Release 129.7 KB 10-Q Q1 2021 2021 Annual Report 2 MB Form of Proxy - for Registered Shareholders 70.9 KB Notice and Access Notification - Internet Availability 166.4 KB Notice of Meeting and Information Circular 355.5 KB Notice of Meeting 77 KB Voting Instruction Form - for non-Registered Shareholders 70.8 KB btn QRs See All Reports Investor Alerts Sign up for investor alerts! Sign Up Information Request Send us a request for information Learn More
Investor Relations Latest News May 13, 2022 InMed Pharmaceuticals Reports Third Quarter Fiscal 2022 Financial Results and Provides Business Update May 05, 2022 InMed to Supply Rare Cannabinoids to Radicle Science’s “Radicle Energy Study” to Assess the Health Effects of THCV Apr 28, 2022 InMed Expands Patent Portfolio with Novel Cannabinoid Analogs and Advances Collaboration Agreement with Leading Cannabinoid Research Expert Apr 21, 2022 InMed Commercializes Cannabidivarin (CBDV), Expanding its Rare Cannabinoid Portfolio for the Health and Wellness Sector btn News See All News Latest Presentation Corporate Presentation - April 2022 Corporate Presentation - April 2022 8 MB More Presentations Latest Events May 23 - May 26, 2022 H.C. Wainwright Global Investment Conference May 11, 2022 Canaccord Genuity’s 6th Annual Global Cannabis Conference April 20 - April 21, 2022 Benzinga Spring 2022 Cannabis Capital Conference btn Events See All Events Videos More Videos btn Stock See All Stock Analyst Coverage Scott R. Henry CFA ROTH Capital Partners shenry@roth.com +1 (406) 425-0563 Ken Mestemacher Edison Research Group kmestemacher@edisongroup.com +1 (646) 653-7027 Raghuram Selvaraju H.C. Wainwright rselvaraju@hcwco.com +1 (212) 916-3966 Latest Financial Reports Show all Q3 2022 Quarterly Press Release 129.7 KB 10-Q Q1 2021 2021 Annual Report 2 MB Form of Proxy - for Registered Shareholders 70.9 KB Notice and Access Notification - Internet Availability 166.4 KB Notice of Meeting and Information Circular 355.5 KB Notice of Meeting 77 KB Voting Instruction Form - for non-Registered Shareholders 70.8 KB btn QRs See All Reports